[Nivolumab and sarcoid reaction in lung cancer treatment]

Rev Mal Respir. 2019 Feb;36(2):230-232. doi: 10.1016/j.rmr.2019.01.002. Epub 2019 Feb 10.

[Article in French]

Authors

J-M Vergnon¹, C L Tissot²

Affiliations

¹ Service de pneumologie et d'oncologie thoracique, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne, France. Electronic address: jean.michel.vergnon@univ-st-etienne.fr.
² Service de pneumologie et d'oncologie thoracique, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne, France.

PMID: 30745234
DOI: 10.1016/j.rmr.2019.01.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Chemotherapy, Adjuvant / adverse effects
Humans
Immunotherapy / adverse effects
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Prognosis
Sarcoidosis / chemically induced*
Sarcoidosis / diagnosis

Substances

Antineoplastic Agents
Nivolumab